Singing Intervention for Chronic Obstructive Pulmonary Disease (COPD) (EMPOWER)
Why is this study being done? Chronic Obstructive Pulmonary Disease (COPD) causes airflow blockage creating breathing issues, distress, and lower well-being. COPD also causes hyperinflation of the lungs. The investigators are doing the study to learn more about improving lung function for patients with COPD by using voice-based experiences.
What is being tested in this study? If singing/vocalizing can improve lung function.
How long will I be in the study? The study will last 4 weeks and involve 2 in-person visits to KUMC with virtual vocal sessions two times a week over Zoom.
調査の概要
詳細な説明
Study Significance: This study is intended to show if air trapping in functional small airways disease (fSAD) in COPD patients is reduced by a targeted music-based singing intervention.
Air trapping in fSAD in COPD is associated with the experience of breathlessness or dyspnea, which is a primary source of patient distress. Air trapping may be mitigated by activities that support slow, controlled, and more complete exhalation. Because singing requires sustained delivery of consistent air pressure for sound production, training in this activity aims to strengthen respiratory musculature to improve airflow control and increase efficient use of each breath. The investigators believe that singing training will be beneficial in strengthening the respiratory musculature and emptying the lungs, possibly reducing the amount of trapped air.
A major gap exists in understanding whether singing is effective for improving lung function in COPD. Previous interventions based in group singing have been focused on improving social and emotional outcomes, but they do not specifically address the potential physiological benefits of singing as described above. The investigators aim to show specific targeted manipulation of music elements within tailored vocalization activities can successfully improve lung function and reduce dyspnea in patients with COPD, while preserving social and emotional benefits of other more generalized singing interventions. The investigators are focusing on air trapping due to small airways disease as a key symptom that leads to patient experience of dyspnea.(13, 14) Other aspects of COPD pathology and symptoms may be improved by the singing intervention, including a sense of hope through a sense of agency in their own psychological health.
The goal of the pilot study is to determine the feasibility of providing a music-based intervention targeting the issue of air trapping, improve functional small airways disease, and improve other symptoms of COPD and further define the details of the intervention.
This study will determine participant acceptability of a newly developed music-based intervention hoped to be beneficial for people with COPD. If successful, our proposed singing intervention will improve lung function health through reduced air trapping due to hyperinflation, improve patient experience of dyspnea and foster positive psychological health.
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
Kansas
-
Kansas City、Kansas、アメリカ、66160
- University of Kansas Medical Center
-
-
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- Participants 18 years of age or older
- Diagnosis of COPD
- Airflow obstruction and resting hyperinflation of the lung
- Able to hear within normal range with correction if needed
Exclusion Criteria:
- Pregnancy will be excluded for CT imaging safety and radiation safety
- Alpha-1 antitrypsin
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:他の
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:4-week singing intervention
Individual virtual singing sessions with a board-certified music therapist designed to target complete exhalation and reduce air trapping
|
Using the Therapeutic Function of Music Plan, this individually tailored music therapy used singing and vocal exercises, guided by a board-certified music therapist, to aid in complete exhalation and reduce air trapping that occurs in chronic obstructive pulmonary disease (COPD).
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Quantitative Computed Tomography (qCT) Air Trapping
時間枠:Change from baseline after four weeks of the EMPOWER intervention
|
Functional Small Airways Disease Percent (range 0-100), indicating non-emphysematous air trapping percentage (fSAD) as lung volume percent of low attenuation areas below a radiodensity of -856 Hounsfield units (HU) on expiratory computed tomography (CT) and above -950HU on inspiratory CT.
Higher values indicate greater air trapping and worse lung function.
|
Change from baseline after four weeks of the EMPOWER intervention
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Forced Expiratory Volume in 1 second (FEV1)
時間枠:Change from baseline after four weeks of the EMPOWER intervention
|
FEV1 measures the maximum volume of air (in Liters) forcefully exhaled in the first second of a coached spirometric assessment or pulmonary function test (PFT).
Lower FEV1 indicates worse lung function and obstructive defect in the lungs.
|
Change from baseline after four weeks of the EMPOWER intervention
|
|
Chronic Obstructive Pulmonary Disease (COPD) Assessment Test (CAT)
時間枠:Change from baseline after four weeks of the EMPOWER intervention
|
Patient reported symptoms of COPD.
The CAT scale contains eight patient-completed questions to assess and monitor COPD symptoms, including the impact on daily life, cough, phlegm, breathlessness, sleep, confidence, and energy.
Scores range from 0-5 on each question for a total scale range of 0-40, with higher scores indicating worse respiratory symptoms.
|
Change from baseline after four weeks of the EMPOWER intervention
|
協力者と研究者
捜査官
- 主任研究者:Rebecca J Lepping, PhD、University of Kansas Medical Center
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- STUDY00160422
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。